Draft synthesis: glucagon-like peptide-1 receptor agonists for weight reduction, version 2
Consultation on the second version of the synthesis of glucagon-like peptide-1 receptor agonists for weight reduction in adults with obesity. The revision re-runs the registered search, adds trials reported since the first version, and reconsiders the anchor…
§1Consultation and window
§1.1Window
- Opened
- 20 January 2026
- Closed
- 21 March 2026
- Duration
- 60 days
- Status
- Closed — the disposition is published
- Document under consultation
- Synthesis: Glucagon-like peptide-1 receptor agonists for weight reduction in…
- Submissions received
- 15
§1.2Consultation questions
The secretariat put the following questions. A submission was not required to address them and several did not; the questions record what the Institute was uncertain about rather than restricting what a respondent could raise.
- Is the high certainty rating for the anchor outcome correctly drawn from the contributing STEP and SURMOUNT trials?
- Should percentage weight change and categorical response at a threshold be reported as two anchor outcomes rather than one with a derived secondary?
- Are the limitations recorded in the abstract sufficient, in particular in relation to the sponsor concentration of the contributing evidence base?
§1.3How a submission is handled
- Every submission is signed. The Institute publishes no anonymous submission.
- Every submission carries a declared interest. A declaration of no interest is itself a declaration and is recorded as one. A declaration is not a disqualification and the Institute has never given a submission less weight on that ground.
- A submission from an employee of a marketing-authorisation holder is identified as an industry submission on its face, following a unanimous consultation on the conflicts policy.
- Every submission receives a secretariat response and a disposition. Submissions that are not accepted remain published in full; the Institute does not remove a submission because it disagrees with it.
- There is no voting, no reputation score, no reply thread and no editing after receipt.
§1.4Outcome
The synthesis was amended before ratification. Percentage change and categorical response are now reported as separate outcomes with separate certainty ratings, and the concentration of the evidence base in sponsor-conducted trials is stated in the abstract rather than in the limitations annex.
The disposition table, listing each submission with its disposition and the resulting amendment, is at §3.